to:!207/899/0968! !!!!!!!!!!!!!!phone:!207/899/0939 ... · pdf file ·...

1
PLEASE FAX TO: 2078990968 PHONE: 2078990939 RHEUMATOLOGY IV ENROLLMENT FORM PATIENT INFORMATION Patient Name: Date of Birth: ! Male ! Female Address: Phone: Alternate Phone: Height: Weight: Insurance Information: ! Attached Allergies: DIAGNOSIS Date of diagnosis: _____ □ Psoriatic arthritis (L40.52) □ Ankylosing spondylitis (M45.9) □ Rheumatoid arthritis (M05) □ Osteoarthritis (M19.90) □ Polyarticular juvenile RA (M08.00) □ Osteoporosis (M81.0) □ Uveitis: NI Intermediate (H_____________) □ Posterior (H_____________) □ Panuveitis (H____________) □ Other: (ICD10 ) PPD skin test performed? □ yes □ no Date: ____________ Current therapy: ______________________________________ Stop before starting new therapy? □ yes □ no Withhold for how long before starting: _____________ Previously failed DMARDs: ______________________________ Previously failed biologics: ______________________________ CLINICAL INFORMATION Current therapy: ______________________________________ Previously failed DMARDs: ____________________________________ Stop before starting new therapy? ! Yes ! No Previously failed biologics: ____________________________________ Withhold for how long before starting: _____________ DRUG DIRECTIONS QTY REFILLS ACTEMRA 20 mg/mL (vial sizes: 4 mL, 10 mL, 20 mL) “maximum dose per infusion: 800 mg” Initial dose: 4 mg/kg __________mg IV every 4 weeks □ 162 mg SQ weekly (>100 kg) Maintenance: 8 mg/kg _________mg IV every 4 weeks ORENCIAIV 250 mg vial □ Less than 60 kg, dose: 500 mg □ 60100 kg, dose: 750 mg □ Greater than 100 kg, dose: 1000 mg New start: IV infusion at week 0, week 2, week 4, then Maintenance dose: IV infusion every 4 weeks REMICADE 100 mg vial New start: _________mg/kg _________ mg IV on week 0, week 2 and week 6, then Maintenance dose: _________mg/kg _________ mg IV every ____ weeks RITUXAN 1000 mg IV infusion As directed on: □ Day 1 & □ Day 15 (will dispense available vial size) □ Other:____________________ RECLAST (5 mg/100mL vial) 5 mg IV every year SIMPONI ARIA (50 mg/4 mL singleuse vial) Initial dose: 2 mg/kg __________mg IV at weeks 0 and 4 Maintenance: 2 mg/kg _________mg IV every 8 weeks ! OTHER: ! Patient is ready to start treatment, contact patient for delivery ! Ship all orders to office ! Ship first order to office, subsequent orders to patient SIGNATURE DATE: PHYSICIAN NAME: DEA #: NPI #: STATE LICENSE #: PRACTICE NAME: ADDRESS: CITY, STATE: ZIP: PHONE #: FAX: OFFICE CONTACT: Your signature authorizes the pharmacy to act on your behalf to obtain prior authorization for the prescribed medications. We will also pursue available copay and financial assistance on behalf of your patients. Following prior authorization, if insurance dictates the prescription be filled at a specific pharmacy ABD will forward the prescription to that pharmacy and the office and patient will be notified 10.03.2016

Upload: lykhanh

Post on 23-Mar-2018

226 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: TO:!207/899/0968! !!!!!!!!!!!!!!PHONE:!207/899/0939 ... · PDF file · 2017-04-21Title: Microsoft Word - Rheumatology IV Enrollment Form ABD   Created Date: 20161003152234Z

 PLEASE  FAX  TO:  207-­‐899-­‐0968                              PHONE:  207-­‐899-­‐0939  

                                                                                   RHEUMATOLOGY  IV  ENROLLMENT  FORM  PATIENT  INFORMATION  

Patient  Name:                                                                                                                                                                          Date  of  Birth:                                                                                          !  Male        !  Female  Address:  Phone:   Alternate  Phone:  Height:                                  Weight:   Insurance  Information:                !  Attached        Allergies:    

DIAGNOSIS  Date  of  diagnosis:       _____          □  Psoriatic  arthritis  (L40.52)                        □  Ankylosing  spondylitis  (M45.9)  □  Rheumatoid  arthritis  (M05)                  □  Osteoarthritis  (M19.90)  □  Polyarticular  juvenile  RA  (M08.00)  □  Osteoporosis  (M81.0)  □  Uveitis:  NI  Intermediate  (H_____________)                                    □  Posterior  (H_____________)          □  Panuveitis  (H____________)  □  Other:                                                                                                                                                (ICD-­‐10  )  

PPD  skin  test  performed?    □  yes        □  no                  Date:  ____________                                  Current  therapy:    ______________________________________  

Stop  before  starting  new  therapy?    □  yes        □  no    Withhold  for  how  long  before  starting:    _____________  

Previously  failed  DMARDs:    ______________________________  Previously  failed  biologics:    ______________________________                                                                        

CLINICAL  INFORMATION  Current  therapy:    ______________________________________                    Previously  failed  DMARDs:  ____________________________________                                      Stop  before  starting  new  therapy?    !  Yes        !  No                                        Previously  failed  biologics:  ____________________________________                                        Withhold  for  how  long  before  starting:    _____________                                                                          DRUG                                                                                                                                                                                                                                                            DIRECTIONS                                                                                                                                                                        QTY                    REFILLS  □  ACTEMRA  20  mg/mL  (vial  sizes:  4  mL,  10  mL,    20  mL)  “maximum  dose  per  infusion:  800  mg”          

□  Initial  dose:  4  mg/kg  __________mg  IV  every  4  weeks  □  162  mg  SQ  weekly  (>100  kg)  □  Maintenance:  8  mg/kg  _________mg  IV  every  4  weeks  

     

□  ORENCIA-­‐IV  250  mg  vial  □  Less  than  60  kg,  dose:  500  mg  □  60-­‐100  kg,  dose:  750  mg            □  Greater  than  100  kg,  dose:  1000  mg                            

□  New  start:  IV  infusion  at  week  0,  week  2,  week  4,  then  □  Maintenance  dose:  IV  infusion  every  4  weeks      

□  REMICADE  100  mg  vial   □  New  start:  _________mg/kg  _________  mg  IV  on  week  0,  week  2  and  week  6,  then      □  Maintenance  dose:  _________mg/kg  _________  mg  IV  every  ____  weeks        

□  RITUXAN  1000  mg  IV  infusion  As  directed  on:    □  Day  1  &                                                                                                                                        □  Day  15  (will  dispense  available  vial  size)                                                                                                                          □  Other:____________________  

   

□  RECLAST  (5  mg/100mL  vial)                                                                       5  mg  IV  every  year      

□  SIMPONI  ARIA  (50  mg/4  mL  single-­‐use  vial)   □  Initial  dose:  2  mg/kg  __________mg  IV  at  weeks  0  and  4    □  Maintenance:  2  mg/kg  _________mg  IV  every  8  weeks      

!  OTHER:            

     

!  Patient  is  ready  to  start  treatment,  contact  patient  for  delivery  !  Ship  all  orders  to  office    

     !  Ship  first  order  to  office,  subsequent  orders  to  patient  

SIGNATURE       DATE:

PHYSICIAN  NAME:   DEA  #: NPI  #: STATE  LICENSE  #:

PRACTICE  NAME: ADDRESS: CITY,  STATE: ZIP:

PHONE  #: FAX: OFFICE  CONTACT:

Your  signature  authorizes  the  pharmacy  to  act  on  your  behalf  to  obtain  prior  authorization  for  the  prescribed  medications.  We  will  also  pursue  available  copay  and  financial  assistance  on  behalf  of  your  patients.  Following  prior  authorization,  if  insurance  dictates  the  prescription  be  filled  at  a  specific  pharmacy  ABD  will  forward  the  prescription  to  that  pharmacy  and  the  office  and  patient  will  be  notified

10.03.2016